Corcept Therapeutics
CORT
246 hedge funds and large institutions have $2.26B invested in Corcept Therapeutics in 2023 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 80 increasing their positions, 92 reducing their positions, and 16 closing their positions.
156% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 16
76% more call options, than puts
Call options by funds: $11.5M | Put options by funds: $6.54M
37% more capital inflows, than outflows
Capital inflows: $164M | Capital outflows: $119M
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
10% more funds holding
Funds holding: 224 → 246 (+22)
0.19% more ownership
Funds ownership: 80.22% → 80.41% (+0.19%)
13% less repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 92
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$23.8M |
| 2 |
Cerity Partners
New York
|
+$14.8M |
| 3 |
Voloridge Investment Management
Jupiter,
Florida
|
+$11.5M |
| 4 |
D.E. Shaw & Co
New York
|
+$10.7M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$10M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$30.9M |
| 2 |
Man Group
London,
United Kingdom
|
-$17.8M |
| 3 |
VOYA Investment Management
Atlanta,
Georgia
|
-$6.22M |
| 4 |
Boston Trust Walden
Boston,
Massachusetts
|
-$4.9M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$4.88M |
CORT Hedge Fund Activity: Q3 2023 in Review
246 of the 6,314 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q3 2023, worth a combined $2.26B — up 25% from $1.81B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new CORT positions and 16 closed out — a net gain of 25 holders — while 80 added to existing stakes and 92 trimmed.
The largest buyer was Arrowstreet Capital, adding an estimated $23.8M. The largest seller was Federated Hermes, cutting an estimated $30.9M.
- 246 institutional investors held Corcept Therapeutics (CORT) as of Q3 2023, up from 224 in Q2 2023.
- Funds reported $2.26B of Corcept Therapeutics stock for Q3 2023, up 25% quarter-over-quarter.
- 41 funds opened new Corcept Therapeutics positions in Q3 2023 and 16 closed out, a net change of +25 holders.
- The largest Corcept Therapeutics buyer in Q3 2023 was Arrowstreet Capital, an estimated $23.8M added.
- The largest Corcept Therapeutics seller in Q3 2023 was Federated Hermes, an estimated $30.9M sold.
Based on aggregated 13F filings for Q3 2023.